The federal government is partnering with biopharmaceutical and biotechnology giants Pfizer and Moderna to help secure millions of vaccine doses to be ready for distribution across Canada in 2021.
Procurement Minister Anita Anand said on Wednesday that the deal with the two multinational corporations will help position Canada at the front of the line when a vaccine is made available.
“Pfizer is evaluating at least four experimental vaccine candidates and is currently undergoing clinical trials. These trials are occurring in various countries including Germany and the United States and they’re already exhibiting promising results,” said Anand during a press conference in Toronto on Wednesday.
The minister didn’t provide detail on how many doses would be developed, or the exact dollar amount of the contract, pointing to ongoing, sensitive negotiations with other suppliers. Pfizer and Moderna’s candidates will require Health Canada approval.
“We have to remember that these suppliers are at various stages of vaccine development. It is important for Canadians to know that we are taking an approach to contractual negations that builds in flexibility for us to be able to increase orders,” Anand said.
“In the weeks to come, I will hope to be disclosing further information.”
There are currently 55 potential COVID-19 drugs, including vaccine candidates, that are currently being investigated in clinical trials authorized by Health Canada.
To be approved for use, any potential vaccine must move through a well-established testing process that involves three phases of human trials. The first and second phases focus on monitoring whether the drug produces the desired response from the human immune system. The third phase involves far more test subjects and aims to determine whether the vaccine candidate is actually able to stop the virus from infecting a body.
Moderna was among the first to develop a vaccine candidate – it was shipped to the U.S. government in February and human testing began in March. The company has said that mRNA-1273 is able to stop the spread of the novel coronavirus in a lab setting, and 30,000 volunteers were given the potential vaccine starting July 27 as part of the final phase of human trials.
Pfizer doses were given to human test subjects in Germany in April and in the U.S. in May. Company CEO Albert Bourla said a few weeks later that one vaccine candidate could be ready by October “if things go well, and the stars are aligned.” Phase III trials began in late July.
Innovation Minister Navdeep Bains, who joined Anand for the announcement Wednesday, underlined the government’s efforts to diversify therapies, which he said will addressed at one of two task forces the Liberals have established.
“Until we immunize all Canadians, we must also focus on producing treatments for those who contract the virus,” he said. “[The task force] will be co-chaired by Nancy Harrison, director and past-chair of LifeSciences B.C. and Cedric Bisson, partner at Teralys Capital.”
Bains also announced $56 million to bolster vaccine development in Canada through Variation Biotechnologies Inc. (VBI).
“Through the Strategic Innovation Fund the government will support VBI’s work on preclinical studies and clinical trials. More investments will follow,” he said.
Both Bains and Anand said they will be working closely with Health Minister Patty Hajdu and Chief Public Health Officer Dr. Theresa Tam on a vaccine rollout plan, which will include decision-making on whether to make vaccination mandatory or voluntary.
On Tuesday, Tam tried to temper expectations that development of a vaccine would mean the coronavirus threat disappears.
“We’re planning, as a public health community, that we’re going to have to manage this pandemic certainly over the next year, but certainly it may be planning for the longer term on the next two to three years during which the vaccine may play a role. But we don’t know yet,” Tam told reporters during a routine COVID-19 press briefing.
Deputy Chief Public Health Officer Dr. Howard Njoo said a vaccine won’t act as a “silver bullet.”
Anand echoed her colleagues’ comments on Wednesday, stating there is no single solution that will transition Canadians entirely out of the pandemic.
“Multiple efforts on multiple fronts must be made and followed,” she said. “We all want a silver bullet but unfortunately that’s not the case. So the approach of the Government of Canada and particularly us in contracting has been to say, ‘Look, we need multiple contracts over multiple periods of time,'” she said.
Infectious disease specialist Dr. Isaac Bogoch told CTV News Channel the announcement signals the government is taking an aggressive and proactive approach to the recovery stage of the pandemic.
“The other interesting thing that Canada is doing is we’ve already purchased 37 million vials to administer a vaccine that we don’t even have just yet so you can just see them taking the steps to really reduce the time from having a successful vaccine trial and approval from health regulatory bodies to administering the vaccine to the population,” he said.
In mid-July the government announced it was ordering more than 75 million syringes, alcohol swabs, and bandages to prepare for an eventual vaccine.
Bogoch added that he suspects health officials to prioritize vaccinating Canadians at greatest risk of contracting the virus, like those in long-term care facilities or those in congregate settings, and those who are likely to experience the virus most severely.
With files from CTV News’ Rachel Aiello and Ryan Flanagan
Feds announce $320M for N.L.'s struggling offshore industry – CBC.ca
The federal government has pledged $320 million to support offshore oil jobs in Newfoundland and Labrador.
Natural Resources Minister Seamus O’Regan was in St. John’s on Friday to announce the new measures, after six months of lobbying from oil industry groups and workers demanding assistance.
O’Regan said the money will “support jobs and ensure the sustainable, long-term, lower-emitting future for our offshore.”
He said it will be spent on safety improvements, maintenance and upgrades of existing offshore infrastructure, environmental services and clean technology.
O’Regan said the money will be handed over to the province with no strings attached and will come from Ottawa’s portion of royalties from the province’s Hibernia oil field.
Newfoundland and Labrador Premier Andrew Furey announced a new task force will decide how the money is spent.
While many details remain unclear, what is known is that the aid does not come in the form that major industry players were rooting for. Husky was asking the federal government to invest in equity stakes in its major projects in the province while offshore advocacy groups like the Newfoundland and Labrador Oil and Gas Industry Assocation — Noia — and the Canadian Association of Petroleum Producers were rooting for tax credits and investment incentives.
In a press release sent after the announcement, CAPP said it needed to see more details but hoped it would lead to immediate help for workers. The group said it will continue pushing for tax reforms and other measures to help stalled projects off the coast of Newfoundland.
Hard times for province’s industry
The announcement comes after six months of crushing losses for the province’s offshore oil industry. Workers took to the steps of Confederation Building last week to speak about the anxiety they feel amid layoffs and cutbacks.
The biggest blow to the province could be still to come. Husky Energy has announced it’s reviewing the West White Rose extension — a $2.1-billion project in Placentia that employs more than 600 people on a daily basis — with the possibility of canning the entire job.
O’Regan said he spoke with Husky on Friday morning, and said the federal government is still at the table over a possible solution for the West White Rose extension.
Problems started in March with the onset of the pandemic in North America coupled with a price war between Saudi Arabia and Russia, which sent oil and gas prices into a nosedive.
Since then, Suncor has anchored its idled Terra Nova FPSO in Conception Bay, the long-standing Hibernia platform has suspended drilling, and future ventures that once sounded lucrative and promising have been shelved.
The result, according to Noia CEO Charlene Johnson, has been thousands of job losses and local companies closing up shop.
O’Regan acknowledged on Friday that the industry is “suffering from a double-whammy.”
He said the new measures are a practical program, “because we believe in our workers. We believe in this industry. And we believe in its future.”
O’Regan also said the federal government is trying to strike deals with the owners of the West Aquarius and Transocean Barents exploratory rigs to support future development in the offshore industry.
The province announced a new incentive for offshore exploration on Thursday. That new measure gives oil companies a chance at a rebate for exploration by taking down payments that would typically go into provincial coffers and offering them back to companies.
Task force details
Furey said the task force will work on an “emergent” basis to get the money out as quickly as possible.
The task force will be chaired by Karen Winsor and Bill Fanning, two former oil executives who are members of the province’s Oil and Gas Industry Development Council — the group to which the task force is reporting.
“The remaining members, to be selected by the council, will bring a diverse mix of skills and experience so that they can contribute to driving the recovery of the Newfoundland and Labrador oil and gas industry,” reads a news release sent to media during Friday’s announcement.
O’Regan said he is OK with putting the province in charge of dishing out the money, since he believes the province should have control of its offshore industry under the Atlantic Accord agreement.
Canada signs deal to secure 20M more COVID-19 vaccine doses, though none have been proven successful yet – CBC.ca
Canada has signed an agreement to secure another 20 million vaccine doses as the global race for a COVID-19 vaccine intensifies.
During a news conference in Ottawa today, Prime Minister Justin Trudeau announced a deal with AstraZeneca on access to a vaccine prospect now being developed at Oxford University. As a result, the federal government has now secured access to six leading vaccine candidates. None of the candidates have been proven to work so far.
“We’ve been guided by science since the very beginning and right now, both the COVID-19 vaccine task force and the immunity task force are doing important work to help us identify the most promising vaccine options and strategies,” he said.
There is no approved vaccine yet for COVID-19, though there are many in clinical trials and in development. Public Services and Procurement Minister Anita Anand said the global market is “intense and unpredictable.”
“Each supplier and therefore each negotiation is unique, with its own set of concerns,” she said. “The resulting agreements contain terms specifying the quantity, the price, the anticipated delivery schedule, the manufacturing and finishing parameters for each vaccine.
“When a vaccine is ready, Canada will be ready.”
The federal government already has reached vaccine agreements with Sanofi, GlaxoSmithKline, Johnson & Johnson, Novavax, Pfizer and Moderna, for a total of 282 million doses.
Full payments to drug companies are contingent on the vaccines passing clinical trials and obtaining regulatory approval.
Health Canada says it will review the evidence on safety, efficacy and manufacturing quality for each vaccine to determine if individual vaccines will be approved for use in Canada before they are made available to Canadians.
Government buying syringes, swabs, needles
The government is also procuring equipment and supplies needed for vaccine manufacturing and packaging, as well as immunization equipment such as syringes, needles and alcohol swabs.
Trudeau also announced that Canada will provide $440 million to COVAX, a global procurement initiative meant to ensure fair, equitable and timely access to vaccines for less wealthy countries.
“This pandemic can’t be solved by any one country alone because to eliminate the virus anywhere, we need to eliminate it everywhere,” Trudeau said.
The U.S. is not participating in the global COVAX project.
Trudeau said the fact that 190 countries are participating — some as contributors, others as recipients — shows that “the world is coming together.”
“Unfortunately, there are a few large countries that have decided not to participate, but I can assure you that the number of countries that have stepped up and participated like Canada is ensuing that we’re going a long way towards having a vaccine accessible for the most vulnerable around the world, which is essential as we move forward to get past this pandemic,” he said.
Rapid test in the works
With frustratingly long waits for COVID-19 tests still the norm in some parts of the country, the federal government is under increasing pressure to approve rapid testing options. Asked about the holdup today, Trudeau said Health Canada accelerated the process to evaluate testing measures this spring.
“But at the same time we have to make sure that every step of the way we are not compromising science or the safety of Canadians,” he said.
Earlier this week, Tam warned that Canada is at a “crossroads” in its pandemic battle and said the actions of individual Canadians will decide whether there will be a massive spike in COVID-19 cases.
Modelling shows the epidemic is accelerating nationally, with projections that cases could climb to more than 5,000 daily by October. If Canadians don’t step up preventative measures, the virus could spread out of control and trigger a wave of infections bigger than the first one, Tam said.
The following day, Trudeau delivered a rare address to the nation with a similar message. He warned that infections could surge and urged Canadians to do their part to prevent transmission by following public health guidelines on masks, gatherings and physical distancing.
Averting a COVID-19 vaccination crisis will take careful communication – The Verge
President Donald Trump’s relentless talk about interference with the COVID-19 vaccine approval process is setting the stage for a vaccination crisis. Even before a vaccine has been approved, public health experts are watching as confidence in a hypothetical vaccine plummets — and they’re already trying to figure out how to win back the public’s trust.
In May, 72 percent of people said that they would get vaccinated, according to a Pew Research Center survey. By September, only half of people said that they would. That drop ispartly driven by the swirling drama around the still-unproven vaccines. Data and study protocols that normally wouldn’t draw much attention are subject to intense scrutiny.
Now, many people who are normally comfortable with vaccines say that they’re worried. They think the process is being driven by politics, not science. They’re concerned that the Trump administration is pressuring federal agencies to authorize a vaccine before there’s enough testing to show that it’s safe or that it works.
It’s still early days, and vaccine development is still in progress. It seems to be unfolding appropriately — at least so far — and it’s still too soon to say what might happen after initial data from the trials is released by pharmaceutical companies. But the drop-off in confidence before a vaccine is available still concerns public health experts. A vaccine won’t be able to help protect people if they don’t take it. If too many people refuse, the population won’t be able to build herd immunity.
Fortunately, there will likely be a long lag between vaccine authorization and the time when most people will actually have the option to get a vaccine. That gives experts room to analyze the data and, if it’s warranted, alleviate some of those fears, says Melanie Kornides, an assistant professor at the University of Pennsylvania School of Nursing who studies vaccine hesitancy. They’ll probably handle it similar to how they handle parents who are scared of the measles vaccine. “We need to address people’s concerns, and talk about the benefits of vaccination,” she told The Verge.
This interview has been lightly edited for clarity.
How warranted are those fears around a politically motivated push to bring a vaccine out too quickly?
I think that we need to remember that a vaccine hasn’t come out yet, and that’s because they haven’t finished safety and efficacy testing. If people are concerned that it’s maybe being pushed through too fast, that hasn’t played out yet because we don’t have a vaccine. I think that we can be confident in communicating that scientists and pharmaceutical companies are taking the right approach of balancing safety and efficacy testing with wanting to end a very dangerous and deadly pandemic as quickly as possible.
Is there a difference between hesitancy around a COVID-19 vaccine and the hesitancy around childhood vaccinations, like the measles vaccine?
I think that there are actually a lot of similarities between the hesitancy that we’re seeing around the COVID-19 vaccine and the normal vaccine hesitancy that we see around childhood vaccinations. As I’m looking at things that people are saying on social media about the COVID-19 vaccine, we see a lot of the same things that people tend to express about childhood vaccination. Those include worries that it’s not effective or worries about unknown, long-term side effects. There are worries that it’s pushed through for commercial profit or to make the government look better. And to some extent, we see with childhood vaccinations this belief that natural immunity might be safer and better, and we’re seeing a little bit of that too with the COVID vaccine.
But the big difference is that this is much more widespread. Many people are saying that they normally get vaccinated and they normally accept vaccines, but they have particular concerns about this vaccine.
Have we seen similar things before, when people who are usually comfortable with vaccines balk at one?
My research before this was really focused on hesitancy around the HPV vaccine. It’s really similar because, like the COVID vaccine, a lot of parents that choose not to vaccinate their children for HPV are not anti-vaxxers. They just say they have these worries that maybe the HPV vaccine wasn’t thoroughly tested, or they’ve seen something on Instagram or Twitter saying that there have been negative side effects that are being taken seriously. You get these parents who are hesitant but, in general, are not anti-vaxxers.
Will the same strategies we use to overcome those worries with HPV vaccines work for a hypothetical COVID-19 vaccine? Are they different from the way you’d talk to someone who is stridently anti-vaccine?
In general, it’s just much harder to convince somebody who has really strong beliefs that vaccinations are dangerous to move over to the pro-vaccine camp. What we do with parents and children is we try to appeal the idea that everybody cares about their child and wants what’s best for their child. It’s about explaining or making them understand that, even though we don’t see these childhood illnesses anymore, they’re very dangerous, and they’re very deadly.
There’s lots of studies showing that the important thing is the trust in the person who’s giving the information to you. I think with COVID-19, what’s going to be important is making sure that health care providers have been really well-trained in communicating the safety and efficacy and importance of the vaccine. That is what goes a long way.
If most of the people who say they won’t get a COVID-19 vaccine are normally okay with vaccines, does that make it easier to help them understand why they should actually take it?
Absolutely. A lot of it is going to depend on how well the safety and efficacy of the vaccine is communicated through the media, through the pharmaceutical companies, and then also through health care providers. But assuming that we do a good job of that, I think that it will move the needle, and a lot of people that are saying they won’t get vaccinated will move over.
If the worst-case scenario does happen — a vaccine actually does get authorized without scientists feeling confident in the data, and there are negative side effects — what might happen?
I think that would definitely be damaging. We have had instances where vaccines have been pulled from the market because they weren’t as safe as the initial safety data suggested. When that happens, it’s usually that the number of negative outcomes is small, but on a population-level, you want to prevent that.
Ideally, hopefully, they’ll have several vaccines around the same time — so if one has to be pulled, the others will continue to be safe and effective.
MLB playoff push: Blue Jays can still catch Yankees after securing berth – Sportsnet.ca
Apple Watch Series 6 review – TechCrunch
After long-term care, Quebec private seniors residences a growing COVID-19 concern – Pipeline News
Silver investment demand jumped 12% in 2019
Iran anticipates renewed protests amid social media shutdown
Richmond BBQ spot speaks out about coronavirus rumours Vancouver Is Awesome
- News23 hours ago
Ontario sees 409 new COVID-19 cases, rolls out $1B updated testing and contact-tracing plan – CBC.ca
- News19 hours ago
CP Holiday Train won't roll across Canada this year due to pandemic – CBC.ca
- Economy21 hours ago
If Donald Trump drags the U.S. economy down, Canada's economy is going along for the ride – Toronto Star
- Business23 hours ago
Tech stocks lift Wall Street as economic rebound slows – Reuters
- News22 hours ago
U.S. cosmetics chain Ulta scraps Canadian expansion plans – CBC.ca
- Art20 hours ago
Pandemic-inspired art exhibit – News 1130
- Media18 hours ago
'Absolutely huge': Media groups optimistic after Liberal pledge to make internet giants pay for content – Financial Post
- Sports19 hours ago
Nate Pearson active for Blue Jays vs. Yankees, expected to pitch in relief – Sportsnet.ca